Thermo Fisher Scientific and Verici DX Collaborate on Pre-Transplant Assay
Verici Dx signed a licensing agreement with Thermo Fisher on an assay for pre-transplant prognostic testing of early kidney rejection risks.
Verici Dx signed a licensing agreement with Thermo Fisher on an assay for pre-transplant prognostic testing of early kidney rejection risks.
With the test, the team demonstrated organ transplant patients are very capable of achieving a good immune response to covid-19 despite immunosuppression.
BD’s quality control media for platelet testing have been CE marked and cleared by FDA.
The molecular test is the first of its type approved to report genotypes as final results.
Read MoreBlood and test utilization management programs can improve patient care while reducing health system costs.
Read MoreThe molecular red blood cell typing test offers the shortest time to reportable results for US hospitals, reference labs, and blood centers.
Read MoreCareSelect Blood features 100 curated transfusion guidelines authored and maintained by the Mayo Clinic.
Read MoreA noninvasive prenatal test for zygosity in twin pregnancies enables obstetricians to triage patients and avoid both overtreatment and undertreatment.
Read MoreThe research developed an optimized workflow for the recovery and culturing of CTCs from a simple blood test to produce an effective ex vivo culture of an individual patient’s cancer cells.
Read MoreThe customizable middleware system centralizes laboratory operations and workflow across hospitals and networks, allowing blood banks and their data to be confidently managed through one central terminal.
Read MoreMQC-CAT from Hemo Bioscience includes both positive and negative red cells and sera.
Read MoreFor point-of-care hemoglobin testing, good capillary blood sampling practices are vitally important.
Read MoreFDA has approved the Cobas Zika test intended to detect the Zika virus in blood donations.
Read MoreThe Panorama noninvasive prenatal test is now validated to screen twin pregnancies for zygosity and chromosomal abnormalities.
Read MoreThe suite of reagents from Ortho Clinical Diagnostics is used to determine the status of a designated antigen on human red blood cells.
Read MoreThe American Red Cross laboratory in Charlotte, NC, is now screening blood samples collected in the states of New Hampshire, New Jersey, Maine, Maryland, Pennsylvania, and Vermont, using the Procleix Babesia assay under an investigational new drug study.
Read MoreThis month’s issue features hematology, blood banking, and organ transplantation products from such companies as Abbott, Advanced Instruments, Helmer Scientific, and Ortho Clinical Diagnostics.
Read MoreThis month’s issue features emerging technologies from such companies as Clinical Genomics, Hamilton Storage, and Symcel.
Read More